Citadel Advisors’s Rein Therapeutics RNTX Stock Holding History

Citadel Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-120,083	Closed	-$139K	–	14626
2025 Q4	$139K	Buy	120,083 +91,882	+326%	+$127K	﹤0.01%	11383
2025 Q3	$32.3K	Sell	28,201 -19,793	-41%	-$25.1K	﹤0.01%	12380
2025 Q2	$67.2K	Buy	+47,994	New	+$86.4K	﹤0.01%	11619
2024 Q2	–	Sell	-13,810	Closed	-$89.8K	–	15641
2024 Q1	$89.8K	Buy	+13,810	New	+$66.1K	﹤0.01%	11502
2021 Q3	–	Sell	-1,511	Closed	-$38K	–	14824
2021 Q2	$38K	Sell	1,511 -831	-35%	-$20.7K	﹤0.01%	13434
2021 Q1	$67K	Buy	+2,342	New	+$80.3K	﹤0.01%	12764
2020 Q4	–	Sell	-2,153	Closed	-$56K	–	11638
2020 Q3	$56K	Buy	+2,153	New	+$50.7K	﹤0.01%	9563
2019 Q4	–	Sell	-628	Closed	-$8K	–	9887
2019 Q3	$8K	Buy	+628	New	+$8.69K	﹤0.01%	9055
2019 Q2	–	Sell	-713	Closed	-$28K	–	9984
2019 Q1	$28K	Sell	713 -313	-31%	-$9.75K	﹤0.01%	9011
2018 Q4	$17K	Buy	+1,026	New	+$41.2K	﹤0.01%	8807
2017 Q3	–	Sell	-634	Closed	-$141K	–	8149
2017 Q2	$141K	Buy	+634	New	+$139K	﹤0.01%	6783

Other funds holding RNTX

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Citadel Advisors's RNTX Position: Q1 2026 in Review

Citadel Advisors sold out of Rein Therapeutics (RNTX) in Q1 2026, closing a stake of 120,083 shares — an estimated $139K sold.

Citadel Advisors first reported a position in RNTX in Q2 2017 and held it in 11 quarters. The position peaked at $141K in Q2 2017. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

Citadel Advisors reported no remaining Rein Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 120,083 Rein Therapeutics shares in Q1 2026, an estimated $139K.
Citadel Advisors first reported a position in Rein Therapeutics in Q2 2017 and held it in 11 quarters.
Citadel Advisors's Rein Therapeutics position peaked at $141K in Q2 2017.
46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.